⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671441 | 0.81 | ALDH1A1 (0.31) | — | |
| SCHEMBL3672317 | 0.79 | ALDH1A1 (0.30) | — | |
| SCHEMBL3672315 | 0.79 | ALDH1A1 (0.30) | — | |
| SCHEMBL3677050 | 0.72 | ALDH1A1 (0.31) | — | |
| SCHEMBL10202604 | 0.71 | — | — | |
| SCHEMBL22959617 | 0.71 | — | — | |
| SCHEMBL21933618 | 0.71 | — | — | |
| SCHEMBL24156003 | 0.71 | — | — | |
| SCHEMBL1109732 | 0.67 | — | — | |
| SCHEMBL3668341 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2016-10-06 | — | — | US | disclosed |
| US-7723423-B2 | Gas-barrier resin composition | CRYOVAC, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1746131-B1 | Gas-barrier resin composition | CRYOVAC INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7285598-B2 | Polymer and process for producing the same | KURARAY CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20070093599-A1 | Gas-barrier resin composition | CRYOVAC, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070021556-A1 | Gas-barrier resin composition | KURARAY CO. LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| EP-1746131-A2 | Gas-barrier resin composition | Cryovac, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060149009-A1 | Produced by ring-opening, in the presence of a metal alkylidene complex comprising a ligand with an imidazolidine structure, a cyclic olefin comprising at least one cyclic olefin further comprising a hydroxy group or a functional group that can be converted into a hydroxy group, and hydrogenating | KURARAY CO., LTD. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1598384-A1 | NOVEL POLYMER AND PROCESS FOR PRODUCING THE SAME | KURARAY CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-6559241-B2 | Process for producing a hydrogenated polymer | KURARAY CO., LTD. (JP) | 2003-05-06 | — | — | US | disclosed |
| US-20020137854-A1 | Process for producing a hydrogenated polymer | KURARAY CO. LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| EP-1241189-A1 | Process for producing a hydrogenated polymer | KURARAY CO., LTD. (JP) | 2002-09-18 | — | — | EP | disclosed |